Patents Assigned to CLB
  • C1 inhibitor muteins and uses thereof
    Patent number: 5622930
    Abstract: Compositions consisting of C1 inhibitor muteins having biological activity similar to C1 inhibitor, but with enhanced resistance to proteolytic cleavage thus rendering such muteins suitable as anti inflammatory agents, preferably for the treatment or prevention of sepsis.
    Type: Grant
    Filed: September 5, 1991
    Date of Patent: April 22, 1997
    Assignee: CLB
    Inventors: Eric Eldering, Lucien Aarden